Work sharing and Resources Sample Clauses

Work sharing and Resources. The assignment of responsibilities for the major activities will be as follows • Chemistry • [***] to perform X-ray Crystallography • [***] to share computational chemistry, medicinal chemistry, laboratory scale–up and early process work to shadow medicinal chemistry ([***]). It should be noted that [***] will provide sufficient access for [***] computational chemists to the software and tools necessary to enable de novo drug design. • [***] to perform library synthesis as relevant. • Biochemistry & Microbiology • [***] to perform ribosomal MOA studies, preliminary MIC90s, and resistance studies. • [***] to do cell free translation assays, time kill, MBC and primary MIC panel. The strains for primary panel and for primary efficacy studies will be from the [***] strain collection. [***] will transfer the cell-translation assay to [***]). • The expanded microbiology panels are to be [***] and or performed by [***], and will need to cover both European and [***] Portions of this Exhibit, indicated by the ▇▇▇▇ “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. • Pharmacology • [***] to perform the [***] assay. • [***] to perform some thigh infection PK/PD studies (different strains/species to those used by [***]). • [***] to perform some thigh infection PK/PD work (different strains/species to those used by [***]). • [***] and/or [***] to set up and use other in-vivo models for compound evaluation if deemed appropriate by the Joint Project Team. • ADMET and Physical Chemistry • [***] to measure protein binding. • [***] to measure thermodynamic aqueous solubilities at pH [***] and [***], microsomal lability, cytotoxicity in HepG2 and CHO cells. • [***] to perform logD @ pH [***], pKa, hepatocyte clearance, CYP profiling (3A4 contribution, inhibition, MBI and induction; 2D6 inhibition), Caco-2-cell permeability, ▇▇▇▇, MNT and hERG and other safety pharmacology studies such as receptor and enzyme profiling for secondary effects. It should be noted that [***] is committed to provide timely access of the collaboration to its ADMET platforms. • Animal Pharmacokinetics (PK - according to intended route(s) of administration) • [***] to perform mouse and rat PK, although it is understood that [***] will be responsible for at least [***] the studies. • [***] to perform [***], which may be outsou...